Introduction {#sec1-0300060516647548}
============

Hepatitis C virus (HCV) infection affects around 185 million people worldwide. Chronic HCV infection can lead to liver fibrosis with occult progression -- a leading cause of cirrhosis and liver cancer, and an indication for liver transplantation.^[@bibr1-0300060516647548]^ Direct-acting antiviral agents (DAAs) have improved the rate of sustained virological response, but patients remain at risk of disease progression.^[@bibr2-0300060516647548]--[@bibr3-0300060516647548]^ Enhanced understanding of HCV--host interactions is required to combat this virus and to develop improved therapies.^[@bibr4-0300060516647548]^

The activation of the sentinel toll-like receptor (TLR) system is an important triggering event in the initial immune defense, inducing both innate and adaptive immunity by recognizing pathogen-associated molecular patterns (PAMPs).^[@bibr5-0300060516647548]--[@bibr6-0300060516647548]^ TLR signaling pathways are strictly co-ordinated by several mechanisms to regulate adequate innate immune responses.^[@bibr7-0300060516647548][@bibr8-0300060516647548]--[@bibr9-0300060516647548]^ Agonists can induce type I interferon (IFN) and antiviral molecules such as 2′-5′ oligoadenylate synthetase (2′-5′OAS) via the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. Suppressor of cytokine signaling (SOCS) family proteins, originally identified as negative-feedback regulators in cytokine signaling, are known to be involved in regulation of TLR-mediated immune responses,^[@bibr10-0300060516647548]^ and SOCS1, a negative regulator of the JAK/STAT pathway, is induced by HCV core protein.^[@bibr9-0300060516647548],[@bibr11-0300060516647548],[@bibr12-0300060516647548]^ In addition, T cell immunoglobulin and mucin domain-3 (Tim-3), a key inhibitory receptor, is expressed on eosinophils, T lymphocytes, dendritic cells, macrophages and lymphoid cells,^[@bibr13-0300060516647548]^ and is overexpressed on T cells in patients with HCV infection or HCV/HIV coinfection.^[@bibr14-0300060516647548][@bibr15-0300060516647548][@bibr16-0300060516647548]--[@bibr17-0300060516647548]^ It has been suggested that Tim-3, which is constitutively expressed by cells of the innate immune system, may synergize with the TLR system to influence a range of inflammatory conditions by promoting or terminating cell immunity.^[@bibr13-0300060516647548]^ Tim-3 may therefore serve opposing roles, and induce distinct signaling in innate and adaptive immune cells.^[@bibr18-0300060516647548]^ The interaction between Tim-3 and its ligand, Galectin-9 (Gal-9), can inhibit the T cell response and induce apoptosis,^[@bibr19-0300060516647548][@bibr20-0300060516647548][@bibr21-0300060516647548]--[@bibr22-0300060516647548]^ suggesting that the Tim-3/Gal-9 pathway may be adopted to escape immune surveillance during chronic viral infection. Blockade of the Tim-3/Gal-9 pathway might help to reinvigorate antiviral immunity and thereby improving the clinical efficacy of current immunotherapies.

Both innate and adaptive immunity have a profound impact on status of HCV infection, and impairment of host immunity may lead to chronic infection.^[@bibr23-0300060516647548],[@bibr24-0300060516647548]^ We have previously shown that TLR3-expressing CD14+ monocyte levels are correlated with treatment response in patients with HCV infection.^[@bibr7-0300060516647548]^ The aim of the present study was to evaluate the role of Tim-3/Gal-9 signaling in chronic HCV infection, and virological response in patients with chronic HCV infection treated with IFN-based therapies. In addition, we aimed to clarify whether TLR3/TLR4 activation and Tim-3 inhibition could induce production of antiviral molecules in human peripheral blood mononuclear cells (PBMCs), which might be beneficial for HCV clearance.

Patients and methods {#sec2-0300060516647548}
====================

Study population {#sec3-0300060516647548}
----------------

Patients aged 18 to 65 years with chronic HCV infection were recruited from Third Hospital of Hebei Medical University, the Fifth Hospital of Shijiazhuang City and Bethune International Peace Hospital (Shijiazhuang, China) between December 2011 and November 2012, with follow-up concluded in May 2014. Diagnosis were made using European Association for the Study of the Liver (EASL) Clinical Practice Guidelines: Management of hepatitis C virus infection^[@bibr25-0300060516647548]^ and the diagnostic criteria of The Guidelines for Prevention and Treatment of Hepatitis C issued by the Chinese Society of Hepatology and Chinese Society of Infectious Diseases and Parasitology of Chinese Medical Association.^[@bibr26-0300060516647548]^ Exclusion criteria were: presence of decompensated cirrhosis; coinfection with HIV, hepatitis A, B or D virus; other causes of chronic liver disease; or comorbidities precluding interferon therapy. A group of age- and sex-matched healthy volunteers who were attending regular health screening and were free from HAV, HBV, HCV, HIV and any other cause of chronic liver disease were recruited as the control group.

The study protocol conformed to the guidelines of the 1975 Declaration of Helsinki and was approved by the ethics committee of Third Hospital of Hebei Medical University, Shijiazhuang, China. All study participants provided written informed consent. All ongoing and related trials for this drug/intervention are registered (ChiCTR-TNRC-10001090).

Blood sampling {#sec4-0300060516647548}
--------------

Peripheral blood (5 ml) was collected into sterile tubes containing 10.8 mg potassium--EDTA from all participants at baseline, and from patients at treatment week 12 and 24 weeks post-treatment. Blood was initially centrifuged at 1200 × ***g*** for 10 min at room temperature, then the supernatant was transferred into a new microcentrifuge tube and centrifuged at 12 000 × ***g*** for 15 min at 4℃ to remove cellular debris. The resulting plasma was stored at −80℃ until further use.

HCV detection {#sec5-0300060516647548}
-------------

Plasma HCV antibodies were detected using a commercial enzyme linked immunosorbent assay (ELISA) kit (Anti-HCV Rapid Test Kit, Livzon diagnostics INC, Zhuhai, China). Plasma HCV RNA was quantified using a qualitative reverse transcriptase polymerase chain reaction (RT--PCR) kit (Cobas Taqman HCV Test, Roche Diagnostics, Indianapolis, IN, USA; lowest limit of detection 15 IU/ml) according to the manufacturer's instructions. HCV genotypes were identified using an HCV genotyping oligochip (Tianjin Third Central Hospital, China).^[@bibr27-0300060516647548]^

Biochemical assays {#sec6-0300060516647548}
------------------

Blood (3 ml) was collecting from participants after an overnight fast, centrifuged at 1200 × ***g*** for 30 min and immediately divided into aliquots. Serum was then frozen and stored at −80℃ until use. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were quantified using an Olympus AU5400 automatic chemical analyser.

Treatment {#sec7-0300060516647548}
---------

Patients with chronic hepatitis C were treated with pegylated IFNα-2a (PegIFNα-2a; 135µg/week for body weight \< 60 kg and 180µg/week for body weight ≥ 60 kg, subcutaneously; Pegasys, Roche, Basel, Switzerland) plus weight-based RBV (13--15 mg/kg per day; Zhejiang Chengyi Pharmaceutical Co., Ltd, Zhejiang, China). Treatment continued for 44 weeks after HCV RNA was undetectable. Standard definitions of responses were used. Complete early virological response (cEVR) was defined as undetectable plasma HCV RNA at week 12 during therapy, and sustained virological response (SVR) was defined as undetectable HCV RNA at 24 weeks after planned end of treatment.

PBMC culture {#sec8-0300060516647548}
------------

Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized peripheral blood (15 ml) from 15 patients and 15 healthy control subjects using Ficoll density gradient centrifugation (Hanyang Biologicals Technology, Tianjin, China). PBMCs were plated in duplicate at 1.0 × 10^6^ cells/well in 24-well plates and divided into five groups: control (untreated); TLR4 agonist group (1µg/ml lipopolysaccharide \[LPS\]); Tim-3 antagonist + TLR4 agonist group (10µg/ml anti-Tim-3 antibody \[Biolegend, San Diego, CA, USA\] for 30 min, supplemented with 1µg/ml LPS); TLR3 agonist group (20µg/ml polyinosinic--polycytidylic acid, \[Poly(I:C)\]) group; Tim-3 antagonist + TLR3 agonist group (10µg/ml anti-Tim-3 antibody for 30 min, supplemented with 20µg/ml Poly\[I:C\]). All cells were incubated at 37℃ with 5% carbon dioxide for 24 h in serum free medium (Botna Biological Technology, Beijing, China) containing 100µg/ml penicillin--streptomycin (North China Pharmaceutical Group Corporation, Hebei, China) and 300µg/ml [l]{.smallcaps}-glutamine (Bio-high Technology, Hebei, China). The supernatant was removed and used for cytokine assays, and the remaining PBMCs were used for RT--PCR for 2′-5′OAS, myxovirus resistance protein A (MxA) and SOCS1.

Cytokine assays {#sec9-0300060516647548}
---------------

Plasma Gal-9 was quantified at baseline (all participants), and treatment week 12 and 24 weeks post-treatment (patients)(Human Galectin 9 ELISA kit, R&D Systems Inc. Minneapolis, MN, USA). Concentrations of IFN-α and tumor necrosis factor-α (TNF-α) in supernatants from PBMC culture were determined using ELISA kits (Human IFN-α and TNF-α ELISA kits, R&D Systems Inc.) according to the manufacturer's instructions. Limits of detection were 0.3 pg/ml for Gal-9, 15 pg/ml for IFN-α and 8 pg/ml for TNF-α. The plates were read on a microplate reader (ELX800; Bio-Tek Instruments, Inc., Winooski, VT).

qRT--PCR {#sec10-0300060516647548}
--------

Total RNA was isolated from PBMCs using TRIzol® (Tiangen Biotech, Beijing, China), according to the manufacturer's instructions. The mRNA concentrations of 2′-5′OAS, MxA and SOCS1 were determined by qRT--PCR using an ABI PRISM 7500 sequence detection system (Applied Biosystems, Foster, CA, USA) with SYBR Green Reagent (Tiangen Biotech). Expression levels of the target genes were normalized against the endogenous reference gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Primer sequences (Sangon Biotech, Shanghai, China) are listed in [Table 1](#table1-0300060516647548){ref-type="table"}. All data were obtained using Sequence Detector Software (Applied Biosystems). Table 1.Primers used for quantitative reverse transcription polymerase chain reaction.GeneProduct lengthPrimer sequences2′-5′OAS279 bpForward 5′-CTGGCGGCTATAAACCTAACC-3′Reverse 5′-GGGCTGTGTTGAAATGTGTTT-3′MxA331 bpForward 5′-CCACCCATATTTCAGGGATCT-3′Reverse 5′-ACTCCATTTGTGGAACTCGTG-3′SOCS1347 bpForward 5′-ATGGTAGCACACAACCAGGTG-3′Reverse 5′-CTAAGGGCGAAAAAGCAGTTC-3′GAPDH87 bpForward 5′-GGCATGGACTGTGGTCATGAG-3′Reverse 5′-TGCACCACCAACTGCTTAGC-3′[^1]

Statistical analyses {#sec11-0300060516647548}
--------------------

Sample size estimation was determined by PASS software (NCSS Statistical Software, Kaysville, UT, USA) based on references and prelimitary experiments. To detect a minimal 71.16 difference in plasma Gal-9 levels (between healthy controls and patients) with α = 0.05, two-tailed and a power of 80%, 11 patients per group were required (*n* = 22 in total). To increase the reliability of the results, 52 patients were recruited. Sample size analysis for IFN-α, 2′-5′OAS, MxA, TNF-α and SOCS1 quantification indicated 15 subjects were required per group for this part of the study.

Data were expressed as mean ± SD or median (range). Statistical analyses were performed with independent *t*-test, one-way analysis of variance (ANOVA) or Kruskal--Wallis *H* test, with the least significant difference-*t* (LSD-*t*) test or Mann--Whitney *U*-test for post-hoc comparison. The χ^2^-test was used to compare categorical data. Correlations between variables were calculated using Spearman rank order correlations. All *P*-values were two-tailed, and were considered significant when \< 0.05. Data were analysed using SPSS® version 16.0 (SPSS Inc., Chicago, IL, USA) for Windows®.

Results {#sec12-0300060516647548}
=======

The study included 52 patients (22 males/30 females; mean age 45.1 ± 13.8 years; age range 18 -- 65 years) and 20 control subjects (9 males/11 females; mean age 44.9 ± 11.7 years; age range 25 -- 60 years). Demographic and clinical characteristics of the study population are given in [Table 2](#table2-0300060516647548){ref-type="table"}. Serum ALT and AST were significantly higher in patients than in controls (*P* = 0.001 and *P* = 0.01, respectively; [Table 1](#table1-0300060516647548){ref-type="table"}). There were no significant between group differences in gender, age, or body mass index. A flowchart indicating progression through the study is shown in [Figure 1](#fig1-0300060516647548){ref-type="fig"}. A total of three patients were lost to follow-up at week 12 of treatment, and a total of ten patients were lost to follow-up at 24 weeks post-treatment. In total, 81.6% (40/49) of patients achieved cEVR, and 73.8% (31/42) achieved SVR. There were no statistically significant between-group differences in any baseline demographic or clinical characteristic when patients were stratified according to cEVR/non cEVR and SVR/non SVR ([Table 3](#table3-0300060516647548){ref-type="table"}). Figure 1.Flow diagram of the progress through the phases of the study. Table 2.Baseline demographic and clinical characteristics of patients with chronic hepatitis C virus (HCV) infection and healthy control subjects included in a study investigating the role of Tim-3/Gal-9 signaling in chronic HCV infection, and virological response in patients with chronic HCV infection treated with interferon-based therapies.CharacteristicControl group *n* = 20Patient group *n* = 52Statistical significance^[a](#table-fn4-0300060516647548){ref-type="table-fn"}^Gender, male/female9/1122/30NSAge, years44.9 ± 11.745.1 ± 13.8NSBMI, kg/m^2^23.4 ± 3.322.3 ± 2.5NSSerum ALT, IU/l21.1 ± 10.657.1 ± 49.2*P* = 0.001Serum AST, IU/l23.3 ± 9.743.6 ± 29.8*P* = 0.01HCV RNA, IU/ml--9.1 × 10^5^ (128 -- 2.5 × 10^7^)Mode of infectionTransfusion--36 (69.2)Previous surgery--4 (7.7)Stomatological treatment--3 (5.8)Other/unknown--9 (17.3)HCV genotype, 1b/2a--46/6[^2][^3][^4][^5] Table 3.Baseline demographic and clinical characteristics of patients with chronic hepatitis C virus (HCV) infection, stratified according to attainment of complete early virological response (cEVR) at treatment week 12 and sustained virological response (SVR) at 24 weeks post-treatment with interferon-based therapy.CharacteristicTreatment week 1224 weeks post-treatmentcEVR *n* = 40non-cEVR *n* = 9SVR *n* = 31non-SVR *n* = 11Gender, male/female19/214/513/184/7Age, years44.5 ± 13.949.5 ± 10.046.0 ± 14.241.6 ± 10.2BMI, kg/m^2^22.0 ± 2.3023.5 ± 2.722.4 ± 2.821.7 ± 1.1Serum ALT, IU/l57.5 ± 49.964.8 ± 40.870.9 ± 51.546.3 ± 40.6Serum AST, IU/l43.2 ± 30.949.5 ± 27.951.6 ± 33.642.7 ± 24.1HCV RNA, IU/ml128--1.1 × 10^7^7.5 × 10^3 ^− 2.5 × 10^7^128--2.5 × 10^7^(5.6 − 98.6) × 10^5^[^6][^7][^8]

Plasma Gal-9 levels were significantly higher in patients than controls at each time point (*P* \< 0.01 for each comparison; [Figure 2(a)](#fig2-0300060516647548){ref-type="fig"}). In patients, Gal-9 levels were significantly lower than baseline at treatment week 12 and at 24 weeks post-treatment (*P* \< 0.01 for each comparison; [Figure 2(a)](#fig2-0300060516647548){ref-type="fig"}). Plasma Gal-9 levels were significantly lower in patients who achieved cEVR than those who did not, at baseline, treatment week 12, and 24 weeks post-treatment (*P* \< 0.05 for each comparison; [Figure 2(b)](#fig2-0300060516647548){ref-type="fig"}). Similarly, Plasma Gal-9 levels at each time point were significantly lower in patients who achieved SVR than those who did not (*P* \< 0.05 for each comparison; [Figure 2(c)](#fig2-0300060516647548){ref-type="fig"}). There was no correlation between plasma Gal-9 level and baseline HCV load (data not shown). Regression analysis showed that there was no relationship between Gal-9 and HCV RNA (data not shown). Figure 2.Plasma concentration of Gal-9 in (a) healthy control subjects and patients with chronic hepatitis C virus (HCV) infection at baseline, treatment week 12 and 24 weeks post-treatment with interferon-based therapy. (b) Patients stratified according to attainment of complete early virological response (cEVR). (c) Patients stratified according to attainment of sustained virological response (SVR). \**P* \< 0.01 and \*\**P* \< 0.001 vs healthy control; ^\#^*P* \< 0.01 vs baseline; △*P* \< 0.05; one-way analysis of variance with least significant difference-*t* test for post hoc comparisons.

Data regarding levels of IFN-α, TNF-α, and 2′-5′OAS, MxA and SOCS1 RNA in PBMC cultures are shown in [Table 4](#table4-0300060516647548){ref-type="table"}. Treatment with TLR3 or TLR4 agonists alone and in combination with Tim-3 antagonist significantly upregulated IFN-α, 2′-5′OAS RNA and MxA RNA compared with untreated control cells, in PBMCs from both patients and healthy control subjects (*P* \< 0.05 for each comparison; [Table 4](#table4-0300060516647548){ref-type="table"}). IFNα levels were significantly lower in patient-derived PBMCs treated with combined TLR4 agonist and Tim-3 antagonist compared with the same treatment in control subject-derived cells (*P* \< 0.05; [Table 4](#table4-0300060516647548){ref-type="table"}). Levels of 2′-5′OAS RNA were significantly lower in patient-derived PBMCs treated with combined TLR4 agonist and Tim-3 antagonist as well as combined TLR3 agonist and Tim-3 antagonist compared with the same treatments in control subject-derived cells (*P* \< 0.05 for each comparison; [Table 4](#table4-0300060516647548){ref-type="table"}). There were no significant differences between patient-derived and control-derived cells in levels of MxA RNA. Table 4.Levels of immune modulators in peripheral blood mononuclear cell (PBMC) cultures from patients with chronic hepatitis C virus infection and healthy controls (*n* = 15/group), cultured in the presence or absence of toll-like receptor (TLR3) and TLR4 agonists (polyinosinic--polycytidylic acid \[Poly(I:C)\] and lipopolysaccharide, respectively) and a T-cell immunoglobulin and mucin domain 3 (Tim-3) antagonist (anti-Tim-3 antibody).ParameterControl groupPatient groupControlTLR4 agonistTim-3 antagonist +  TLR4 agonistTLR3 agonistTim-3 antagonist  + TLR3 agonistControlTLR4 agonistTim-3 antagonist  + TLR4 agonistTLR3 agonistTim-3 antagonist  + TLR3 agonistIFN-α, pg/ml25.5 ± 1.4306.4 ± 63.4^[a](#table-fn11-0300060516647548){ref-type="table-fn"}^377.7 ± 69.9^[a](#table-fn11-0300060516647548){ref-type="table-fn"}^326.3 ± 54.0^[a](#table-fn11-0300060516647548){ref-type="table-fn"}^665.2 ± 129.4^[a](#table-fn11-0300060516647548){ref-type="table-fn"}bcd^33.3 ± 1.9258.4 ± 56.2^[a](#table-fn11-0300060516647548){ref-type="table-fn"}^292.9 ± 72.8^[a](#table-fn11-0300060516647548){ref-type="table-fn"}e^312.0 ± 56.9^[a](#table-fn11-0300060516647548){ref-type="table-fn"}^623.5 ± 101.6^[a](#table-fn11-0300060516647548){ref-type="table-fn"}bcd^2′-5′OAS RNA1.0 ± 0.23.2 ± 0.8^[a](#table-fn11-0300060516647548){ref-type="table-fn"}^6.7 ± 0.9^[a](#table-fn11-0300060516647548){ref-type="table-fn"}b^4.8 ± 1.4^[a](#table-fn11-0300060516647548){ref-type="table-fn"}bc^8.5 ± 1.7^[a](#table-fn11-0300060516647548){ref-type="table-fn"}bcd^1.0 ± 0.32.4 ± 0.6^[a](#table-fn11-0300060516647548){ref-type="table-fn"}^4.4 ± 0.7^[a](#table-fn11-0300060516647548){ref-type="table-fn"}be^4.2 ± 0.9^[a](#table-fn11-0300060516647548){ref-type="table-fn"}b^6.3 ± 1.2^[a](#table-fn11-0300060516647548){ref-type="table-fn"}bcde^MxA RNA1.0 ± 0.13.2 ± 0.5^[a](#table-fn11-0300060516647548){ref-type="table-fn"}^4.5 ± 0.8^[a](#table-fn11-0300060516647548){ref-type="table-fn"}b^3.4 ± 0.6^[a](#table-fn11-0300060516647548){ref-type="table-fn"}c^6.7 ± 0.7^[a](#table-fn11-0300060516647548){ref-type="table-fn"}bcd^1.1 ± 0.43.3 ± 1.0^[a](#table-fn11-0300060516647548){ref-type="table-fn"}^4.4 ± 0.7^[a](#table-fn11-0300060516647548){ref-type="table-fn"}b^3.8 ± 0.7^[a](#table-fn11-0300060516647548){ref-type="table-fn"}^5.7 ± 0.2^[a](#table-fn11-0300060516647548){ref-type="table-fn"}bcd^SOCS1 RNA1.1 ± 0.21.7 ± 0.4^[a](#table-fn11-0300060516647548){ref-type="table-fn"}^1.7 ± 0.2^[a](#table-fn11-0300060516647548){ref-type="table-fn"}^2.2 ± 0.5^[a](#table-fn11-0300060516647548){ref-type="table-fn"}bc^1.4 ± 0.22.5 ± 0.6^e^4.0 ± 0.8^[a](#table-fn11-0300060516647548){ref-type="table-fn"}e^2.5 ± 0.2^be^4.0 ± 0.8^[a](#table-fn11-0300060516647548){ref-type="table-fn"}ce^1.5 ± 0.4^[a](#table-fn11-0300060516647548){ref-type="table-fn"}be^TNF-α, pg/ml15.9 ± 3.229.5 ± 5.4^[a](#table-fn11-0300060516647548){ref-type="table-fn"}^25.9 ± 7.2^[a](#table-fn11-0300060516647548){ref-type="table-fn"}^22.1 ± 6.8^[a](#table-fn11-0300060516647548){ref-type="table-fn"}^18.8 ± 4.316.3 ± 4.129.7 ± 5.1^[a](#table-fn11-0300060516647548){ref-type="table-fn"}^26.7 ± 6.9^[a](#table-fn11-0300060516647548){ref-type="table-fn"}^25.7 ± 6.0^[a](#table-fn11-0300060516647548){ref-type="table-fn"}^22.7 ± 6.9[^9][^10][^11]

In both patient-derived and control-derived cells, levels of IFN-α, 2′-5′OAS RNA and MxA RNA were significantly upregulated by combined TLR4 agonist and Tim-3 antagonist treatment compared with TLR4 agonist alone, and by combined TLR3 agonist and Tim-3 antagonist treatment compared with TLR3 agonist alone (*P* \< 0.05 for each comparison; [Table 4](#table4-0300060516647548){ref-type="table"}).

Treatment of both patient-derived and control-derived cells with TLR3 or TLR4 agonists significantly upregulated both SOCS1 RNA and TNF-α compared with untreated cells (*P* \< 0.05 for each comparison; [Table 4](#table4-0300060516647548){ref-type="table"}). In patient-derived cells, the addition of Tim-3 antagonist to TLR4 or TLR3 agonist treated cultures significantly reversed the increase in SOCS1 RNA (*P \< *0.05 for each comparison; [Table 4](#table4-0300060516647548){ref-type="table"}). In control-derived cells, the addition of Tim-3 antagonist significantly reversed the increase in SOCS1 RNA in TLR3 treated cultures (*P \< *0.05; [Table 4](#table4-0300060516647548){ref-type="table"}) but not in TLR4 agonist treated cultures. In both patient- and control-derived cells, the addition of Tim-3 antagonist had no effect on TNF-α levels in TLR4 agonist treated cultures, but significantly reversed the increase in TLR3 agonist treated cells (*P \< *0.05; [Table 4](#table4-0300060516647548){ref-type="table"}).

In all treatment groups except Tim-3 antagonist/TLR3 combined treatment, levels of SOCS1 RNA were significantly higher in patient-derived cells compared with control-derived cells (*P \< *0.05 for each comparison; [Table 4](#table4-0300060516647548){ref-type="table"}). There were no significant differences between patient-derived and control-derived cells in levels of TNF-α.

Discussion {#sec13-0300060516647548}
==========

The initial aim of this study was to investigate the dynamic changes in plasma Gal-9 levels in patients with chronic HCV infection undergoing PegIFNα-2/RBV treatment. Plasma Gal-9 levels were significantly elevated in patients with chronic HCV infection compared with healthy control subjects in the present study, suggesting that persistent high Gal-9 levels might contribute to refractory chronic hepatitis C. Antiviral treatment significantly reduced plasma Gal-9 levels compared with baseline in our patient cohort, particularly in those patients who achieved cEVR or SVR. Gal-9 may play an important role in the immune response.^[@bibr28-0300060516647548]^ This indicated that the antiviral therapies could down-regulate the expressions of inhibitory molecule Gal-9 and related to the restoration of immune modulatory activity of Tim-3/Gal-9 pathway, which might improve outcomes of IFNα-based therapy for HCV infection.

Our previous study demonstrated that TLR3 expressing CD14 + monocytes were present in significantly lower numbers in patients who achieved cEVR than those who did not.^[@bibr4-0300060516647548]^ TLR3 and TLR4 agonists have been shown to have significant efficacy against HCV,^[@bibr7-0300060516647548]^ and both can induce antiviral molecules such as 2′-5′OAS.^[@bibr9-0300060516647548]^ In the present study, TLR3 and TLR4 agonists increased the levels of IFN-α, and 2′-5′OAS and MxA RNAs. The combination of TLR3/TLR4 agonist and Tim-3 antagonist further stimulated expression of these antiviral proteins in the current study, with TLR3 agonist + Tim-3 antagonist shown to have the strongest inducer of anti-HCV molecules. These findings suggest that activation of TLR3 alone or in combination with Tim-3 suppression may produce an effective antiviral response and represent a possible approach for immune therapy in patients with chronic HCV infection.

The induction of the proinflammatory cytokine TNF-α was evaluated in the present study in order to determine the potential side effects of the TLR agonists and Tim-3 antagonist. TNF-α is a key proinflammatory cytokine, high levels of which have been shown to aggravate liver injury and result in a low response rate to IFN-α based antiviral therapy in patients with HCV infection.^[@bibr29-0300060516647548]^ Blocking of Tim-3 on the surface of monocytes has been shown to inhibit TNF-α expression.^[@bibr30-0300060516647548]^ Combination treatment of PBMCs with TLR3/TLR4 agonist and Tim-3 antagonist significantly reduced TNF-α levels compared with TLR3/TLR4 agonist alone in the present study. Interestingly, the addition of Tim-3 antagonist to TLR3 agonist treated cells completely ameliorated the increase in TNF-α levels seen with TLR3 agonist treatment alone. These findings suggest that comodulation of TLR3 and Tim-3 may provide a treatment option for HCV infection, suppressing inflammatory response while enhancing antiviral activity.

The negative immune-regulator SOCS1 was upregulated by treatment with TLR3 or TLR4 agonist in the present study. This may be due to induction of type 1 IFN by TLR, activating the JAK/STAT pathway and inducing SOCS1 expression.^[@bibr11-0300060516647548]^ It has been reported that Tim-3 and SOCS1 communicate with each other and co-ordinately inhibit cell signalling transduction, resulting in impaired innate immune response.^[@bibr12-0300060516647548],[@bibr20-0300060516647548]^ Culture with a combination of TLR3 agonist and Tim-3 antagonist did not induce SOCS1 expression in the present study, suggesting that blockade of Tim-3 could suppress SOCS1 expression induced by TLR

The present study had several limitations. In order to gain insight into the underlying mechanism and therapeutic role of modulation of TLRs and the Tim-3/Gal-9 pathway, large-scale studies and further research are required. In addition, T cells should be isolated from PBMCs for in vitro experiments, and the activation of effector T cell subsets and expression of related cytokines should be determined in patients with chronic HCV infection.

In conclusion, plasma Gal-9 levels were significantly upregulated in patients with chronic HCV infection, and were significantly reduced by antiviral treatment with IFN-based therapy. Low plasma Gal-9 levels before, during, and after antiviral therapy were crucial to achieve early and sustained virological responses. Blockade of Tim-3 in combination with TLR activation, especially TLR3, induces the expression of antiviral molecules without a significant increase in the proinflammatory TNF-α or the negative immune-regulator SOCS1, indicating a possible therapeutic approach for patients with chronic HCV infection.
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[^1]: 2′-5′OAS, 2′-5′ oligoadenylate synthetase; MxA, myxovirus resistance protein A; SOCS1, suppressor of cytokine 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

[^2]: Data presented as *n* (%), mean ± SD, or median (range).

[^3]: BMI, body mass index; ALT, alanine transaminase; AST, aspartate transaminase.

[^4]: Independent *t*-test or χ^2^-test.

[^5]: NS, not statistically significant (*P* ≥ 0.05).

[^6]: Data presented as *n* (ratio), mean ± SD, or range.

[^7]: BMI, body mass index; ALT, alanine transaminase; AST, aspartate transaminase.

[^8]: No statistically significant between-group differences (*P* ≥ 0.05; independent *t*-test or χ^2^-test).

[^9]: Data presented as mean ± SD

[^10]: IFN, interferon; TNF, tumour necrosis factor; 2′-5′OAS, 2′-5′ oligoadenylate synthetase; MxA, myxovirus resistance protein A; SOCS1, suppressor of cytokine 1.

[^11]: *P* \< 0.05 vs control cells in same group; ^b^*P* \< 0.05 vs LPS-treated cells in same group; ^c^*P* \< 0.05 vs Anti-Tim-3 + LPS-treated cells in same group; ^d^*P* \< 0.05 vs Poly(I:C)-treated cells in same group; ^e^*P* \< 0.05 vs same treatment in control group; one-way analysis of variance with least significant difference-*t* test for post hoc comparison.
